{"id":27763,"date":"2026-02-15T20:20:13","date_gmt":"2026-02-15T14:50:13","guid":{"rendered":"https:\/\/signalz.pro\/?post_type=article&p=27763"},"modified":"2026-02-15T20:20:13","modified_gmt":"2026-02-15T14:50:13","slug":"abbotindia-%e0%a4%b9%e0%a5%87%e0%a4%b2%e0%a5%8d%e0%a4%a5%e0%a4%95%e0%a5%87%e0%a4%af%e0%a4%b0-%e0%a4%95%e0%a4%be-%e0%a4%ad%e0%a4%b0%e0%a5%8b%e0%a4%b8%e0%a5%87%e0%a4%ae%e0%a4%82%e0%a4%a6-%e0%a4%b8","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/abbotindia-%e0%a4%b9%e0%a5%87%e0%a4%b2%e0%a5%8d%e0%a4%a5%e0%a4%95%e0%a5%87%e0%a4%af%e0%a4%b0-%e0%a4%95%e0%a4%be-%e0%a4%ad%e0%a4%b0%e0%a5%8b%e0%a4%b8%e0%a5%87%e0%a4%ae%e0%a4%82%e0%a4%a6-%e0%a4%b8\/","title":{"rendered":"“ABBOTINDIA: \u0939\u0947\u0932\u094d\u0925\u0915\u0947\u092f\u0930 \u0915\u093e \u092d\u0930\u094b\u0938\u0947\u092e\u0902\u0926 \u0938\u093e\u0925\u0940, \u092d\u0935\u093f\u0937\u094d\u092f \u0915\u0940 \u0926\u0935\u093e \u092e\u0947\u0902 \u0905\u0917\u094d\u0930\u0923\u0940!”"},"content":{"rendered":"

Technical Analysis
\n<\/strong>Current price \u20b926,460 (-1.69%, Feb 13, 2026 close), open \u20b926,680, high \u20b926,685, low \u20b926,300; 52W high \u20b937,000\/low \u20b926,300. Strong Sell signals: Most MAs bearish (MA5 \u20b934,372 Sell to MA200 \u20b933,680 Buy – 9 Sell\/3 Buy), RSI 41 Sell, STOCH 97 Overbought, MACD +54 Buy but ADX 43 Sell, CCI -82 Sell; high volume \u20b9275. Pivot levels: PP \u20b931,387-34,187, R1 \u20b931,810-34,274, S1 \u20b930,525-34,103; key support \u20b930,020-29,240, resistance \u20b932,590-34,443. Downtrend persists but STOCHRSI oversold hints at reversal if \u20b926,300 holds. Long-term position: Yes for quality pharma play.<\/p>\n

Fundamental Analysis
\n<\/strong>Q3 FY26: Net sales \u20b91,724 Cr (+6.79-6.80% YoY, -1.88% QoQ), PAT \u20b9376 Cr (+4.20% YoY), EBIT margin pressure but 9M sales +8.69% \u20b95,220 Cr, PAT +7.67% \u20b91,157 Cr. Zero debt, ROE 32.53%, high ROCE; PE 36.89-37.60, premium P\/B, market cap \u20b956,226 Cr. Brand strength and R&D investments shine.<\/p>\n

Continuous Downfall Reasons\/Reversal Outlook
\n<\/strong>Yes, 25% decline from \u20b937K highs: Market underperformance, weak trading momentum, investor participation down 12.51%, flat Q3 results, high valuations (P\/B\/PEG), profit booking. Rally unlikely to continue\u2014reversal possible at 52W low test\/oversold conditions, though downtrend dominates short-term. Long-term: Accumulate given zero debt\/high ROE.<\/p>\n

Recent News Events
\n<\/strong>Q3 results (Feb 11-12): PAT +4%, revenue +7% but margin squeeze\u2014shares declined post-earnings.
\nBoard changes (Dec 2025): Ambati Venu resignation, Vivek Mohan appointment Jan 2026.
\nUnion Budget 2026: \u20b910K Cr Biopharma Shakti boost. Impact: Short-term negative, long-term positive.<\/p>\n

Positive Points
\n<\/strong>Q3\/9M PAT +4%\/7.67%, zero debt, ROE 32.53%.
\nBudget biopharma push, new products\/market share gains.
\nHigh management efficiency, 1Y +21% long-term performance.<\/p>\n

Negative Points
\n<\/strong>Margin pressure, QoQ revenue dip, elevated valuations.
\nInvestor participation -12.51%, short-term downtrend.
\nSTOCH overbought amid overall Strong Sell signals.<\/p>\n

Macro View
\n<\/strong>Pharma sector boosted by Budget biopharma\/R&D allocations, rising healthcare demand; US price controls pose risks.<\/p>\n

Micro View
\n<\/strong>Strong therapeutic segments (distribution\/R&D), brand leadership but cost management challenges persist.<\/p>\n

Disclaimer
\n<\/strong>This analysis is for informational and educational purposes only and does not constitute investment, financial, tax, legal, or any other advice. Stock markets are subject to substantial risks, including possible loss of principal. Past performance does not guarantee future results. Investors should conduct independent research, assess risk tolerance and financial situation, and consult qualified financial advisors or SEBI-registered professionals before any investment decisions.
\nInvestogainer Research assumes no liability for losses from reliance on this report. Data sourced from public domains as of Feb 15, 2026.<\/p>\n

Conflict of Interest Disclosure
\n<\/strong>Investogainer Research (SEBI Reg No. INH000012856, BSE Enlistment No. 5845, Website: www.investogainerresearch.com), its directors, employees, associates, or related entities hold no direct\/indirect positions, derivatives, or significant stakes (>1%) in Abbott India Ltd (ABBOTINDIA). No compensation or incentives are tied to this analysis. All views are independent, based solely on public data.<\/p>\n

 <\/p>\n

\u200b<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[130,163,112,235,92,129,162,168,127,155],"class_list":["post-27763","article","type-article","status-publish","hentry","article-category-learn","article-tags-expert-analysis","article-tags-financialeducation","article-tags-financialplanning","article-tags-nifty50","article-tags-sebi-registered-advisors","article-tags-stock-market-tips","article-tags-stockmarket","article-tags-stockmarkettips","article-tags-successful-investing","article-tags-wealthbuilding"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/27763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=27763"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=27763"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=27763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}